ASCO: Merck overshadowed by upstart biotechs but TROP2 plans begin to pay off
BioSpace
Merck may not have had the splashiest presentation at the American Society of Clinical Oncology meeting, but the data show why the Big Pharma remains king of oncology, analysts say.
pharminent
June 2, 2026 (Last updated: June 4, 2026)
BioSpace
Merck may not have had the splashiest presentation at the American Society of Clinical Oncology meeting, but the data show why the Big Pharma remains king of oncology, analysts say.
